Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.